You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

~ Buy the CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CONTRAVE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Contrave, and when can generic versions of Contrave launch?

Contrave is a drug marketed by Nalpropion and is included in one NDA. There are twenty-two patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventy-two patent family members in forty-four countries.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Contrave

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CONTRAVE?
  • What are the global sales for CONTRAVE?
  • What is Average Wholesale Price for CONTRAVE?
Drug patent expirations by year for CONTRAVE
Drug Prices for CONTRAVE

See drug prices for CONTRAVE

Recent Clinical Trials for CONTRAVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Currax PharmaceuticalsPhase 4
Novo Nordisk A/SPhase 4
University of California, Los AngelesEarly Phase 1

See all CONTRAVE clinical trials

Paragraph IV (Patent) Challenges for CONTRAVE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CONTRAVE Extended-release Tablets bupropion hydrochloride; naltrexone hydrochloride 8 mg/90 mg 200063 1 2015-03-12

US Patents and Regulatory Information for CONTRAVE

CONTRAVE is protected by twenty-two US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes 8,722,085 ⤷  Subscribe ⤷  Subscribe
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes 8,318,788 ⤷  Subscribe ⤷  Subscribe
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes 10,307,376 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CONTRAVE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 11,278,544 ⤷  Subscribe
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 7,462,626 ⤷  Subscribe
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 8,815,889 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CONTRAVE

See the table below for patents covering CONTRAVE around the world.

Country Patent Number Title Estimated Expiration
Spain 2924024 ⤷  Subscribe
European Patent Office 3730132 COMPOSITION À UTILISER DANS UNE MÉTHODE DE TRAITEMENT DE LA SURCHARGE PONDÉRALE ET DE L'OBÉSITÉ CHEZ DES PATIENTS PRÉSENTANT UN RISQUE CARDIOVASCULAIRE ÉLEVÉ (COMPOSITION FOR USE IN A METHOD OF TREATING OVERWEIGHT AND OBESITY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK) ⤷  Subscribe
Germany 602004012403 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CONTRAVE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 17C1058 France ⤷  Subscribe PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456 65/2017 Austria ⤷  Subscribe PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330
2316456 122017000109 Germany ⤷  Subscribe PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

CONTRAVE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for CONTRAVE (Naltrexone-Bupropion)

Introduction

CONTRAVE, a combination of naltrexone and bupropion, is a prescription weight loss medication that has been a significant player in the anti-obesity drug market. Here, we will delve into the market dynamics and financial trajectory of CONTRAVE, highlighting its performance, challenges, and future outlook.

Market Overview

The global anti-obesity medication market is experiencing robust growth, driven by the increasing prevalence of obesity. This trend is expected to continue, with the market projected to reach USD 4.8 billion by 2030, growing at a CAGR of 8.7% from 2023 to 2030[4].

CONTRAVE Market Performance

Historical Sales and Growth

In the first quarter of 2017, Orexigen Therapeutics, the manufacturer of CONTRAVE, reported significant growth in U.S. sales. The company achieved a 39% increase in prescriptions compared to Q4 2016 and a 22% growth in average net revenue per unit sold compared to the first quarter of 2016. This growth was attributed to the company's patient-centric campaign and the expansion of its telemedicine pilot program[2].

Revenue and Prescription Volume

During the first quarter of 2017, Orexigen reported $19.1 million in revenue, with $14.8 million coming from net sales of CONTRAVE in the United States. The total prescriptions of CONTRAVE filled in the first quarter of 2017 were 195,920, showing a slight increase from the 192,005 prescriptions filled in the first quarter of 2016[2].

Competitive Landscape

The anti-obesity drug market is highly competitive, with several key players including Novo Nordisk, GSK, Novartis, and VIVUS LLC. CONTRAVE faces competition from other approved and emerging therapies. For instance, Saxenda (semaglutide) currently dominates the market, but newer drugs like semaglutide and other pipeline products are expected to provide significant competition to CONTRAVE[3][4].

Regulatory and Developmental Activities

CONTRAVE has undergone various regulatory milestones and developmental activities. The drug has been approved for weight loss in several countries, and its market size is forecasted to grow in key regions such as the United States, Germany, France, Spain, Italy, the UK, and Japan. Detailed analyses of forecasted sales data from 2019 to 2032 provide insights into the drug's market performance and potential[1].

Financial Trajectory

Revenue Projections

The market size for CONTRAVE is expected to grow significantly over the coming years. For example, in the United States, the market size for CONTRAVE is projected to increase substantially from 2019 to 2032. Similar growth trends are expected in other major markets like Germany, France, and the UK[1].

Operating Expenses and Net Loss

Despite the growth in sales, Orexigen faced significant operating expenses in 2017, primarily related to establishing and managing sales, marketing, and distribution capabilities. The company reported a net loss of $69.1 million in the first quarter of 2017, compared to a net loss of $22.3 million in the first quarter of 2016. However, the company had $126.6 million in cash, restricted cash, and marketable securities as of March 31, 2017[2].

Market Drivers and Challenges

Rising Obesity Prevalence

The escalating prevalence of obesity is a major driver for the anti-obesity drug market. Governments and healthcare organizations are prioritizing obesity prevention and treatment, which is expected to drive the market's growth[3].

Regulatory Challenges

Despite the positive outlook, the anti-obesity drug market faces regulatory challenges. For instance, the launch of new therapies and the stringent regulatory environment can impact the market dynamics of existing drugs like CONTRAVE[4].

Patient and Physician Reluctance

Reluctance among patients, physicians, and payers due to past setbacks with anti-obesity drugs can also pose challenges to the market growth of CONTRAVE. However, ongoing efforts in new drug development and innovative marketing strategies are expected to mitigate these challenges[4].

Strategic Initiatives and Partnerships

Commercial Strategies

Orexigen has implemented various commercial strategies to boost the sales of CONTRAVE. These include a comprehensive digital and social-media marketing strategy, the expansion of telemedicine services, and distribution agreements with partners in different regions[2].

Global Expansion

The company has also worked on expanding the reach of CONTRAVE through partnerships. For example, Orexigen executed distribution agreements for the commercialization of Mysimba (the European brand name for CONTRAVE) in several countries, including Italy, Denmark, Finland, Norway, Sweden, and Iceland[2].

Future Outlook

Market Growth

The anti-obesity medication market, including CONTRAVE, is expected to grow significantly due to the increasing prevalence of obesity and the need for effective treatments. The market is projected to reach USD 77.24 billion by 2030, expanding at a CAGR of 31.66% from 2024 to 2030[3].

Competitive Positioning

While CONTRAVE faces stiff competition, its unique mechanism of action and established market presence position it as a viable option in the anti-obesity drug market. Newer drugs and therapies will continue to shape the competitive landscape, but CONTRAVE is expected to maintain its relevance through ongoing marketing efforts and strategic partnerships[1][4].

Key Takeaways

  • Market Growth: The anti-obesity medication market is growing rapidly, driven by the increasing prevalence of obesity.
  • Competitive Landscape: CONTRAVE faces competition from other approved and emerging therapies but remains a significant player.
  • Financial Performance: Despite growth in sales, Orexigen has faced significant operating expenses and net losses.
  • Regulatory and Developmental Activities: CONTRAVE has undergone various regulatory milestones and developmental activities.
  • Strategic Initiatives: Orexigen has implemented several commercial strategies and partnerships to boost CONTRAVE's sales.

FAQs

Q: What is the projected market size for the anti-obesity medication market by 2030? A: The global anti-obesity medication market is projected to reach USD 77.24 billion by 2030, expanding at a CAGR of 31.66% from 2024 to 2030[3].

Q: How has CONTRAVE performed in terms of sales and prescription volume? A: In the first quarter of 2017, CONTRAVE achieved a 39% increase in prescriptions and a 22% growth in average net revenue per unit sold compared to the first quarter of 2016[2].

Q: What are the main challenges faced by CONTRAVE in the market? A: CONTRAVE faces challenges such as competition from other therapies, regulatory hurdles, and reluctance among patients, physicians, and payers[4].

Q: What strategic initiatives has Orexigen taken to boost CONTRAVE's sales? A: Orexigen has implemented a comprehensive digital and social-media marketing strategy, expanded telemedicine services, and executed distribution agreements with partners in different regions[2].

Q: How does the future outlook for CONTRAVE look in the anti-obesity drug market? A: Despite competition, CONTRAVE is expected to maintain its relevance through ongoing marketing efforts and strategic partnerships, with the market projected to grow significantly due to the increasing prevalence of obesity[1][3].

Sources

  1. ResearchAndMarkets.com: CONTRAVE (Naltrexon-Bupropion), Drug Insight and Market Forecast.
  2. Biospace: Orexigen Reports Financial Results For The First Quarter Ended March 31, 2017.
  3. GlobeNewswire: Global Anti-obesity Medication Market Trends Analysis Report 2024-2030.
  4. GlobeNewswire: Anti-Obesity Drugs Global Strategic Business Report 2024.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.